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Abstract
Introduction The number of cancer survivors experiencing
disease progression (DP) is increasing with the number of
cancer survivors. However, little is known whether DP
affects health-related quality of life (HRQL) of long-term
cancer survivors. We aimed therefore to compare the health
status (HS) and HRQL of DP and disease-free (DF)
survivors up to 15 years after initial diagnosis.
Methods 232 cancer survivors with DP identified through
the Eindhoven Cancer Registry were matched with 232 DF
survivors of similar demographic and clinical characteristics.
Patients completed generic HS (SF-36) and cancer-specific
HRQL (QOL-CS) questionnaires 5–15 years after diagnosis.
Results Compared with DF survivors, DP survivors
exhibited significantly lower scores on all SF-36 and QOL-
CS (except spiritual well-being) dimensions. DF survivors
had better scores than the normative population on all SF-36
dimensions. Among survivors with DP, those with short
survival (<5 years) had significantly poorer HS scores on all
dimensions except bodily pain compared with the normative
population. Comparatively, the long survival (≥5 years) DP
group had better HRQL than the short DP group but poorer
HRQL than the normative population. In multivariate
analyses, DP and DF survival time were independently
associated with aspects of HS and HRQL in cancer
survivors.
Discussions/Conclusions DP cancer survivors have poorer
long-term HS and HRQL compared with DF survivors.
However, there is suggestion that HS and HRQL does
improve over time following DP.
Implication for Cancer Survivors Although DP survivors
report poorer long-term HRQL compared with DF cancer
survivors, results suggest that time can attenuate the distress of
DP on HRQL. Psycho-educational programs could help to
increase patients’ sense of empowerment and personal control
should DP occur.
Keywords Cancer . Disease progression . Health status .
Long-term survivors . Quality of life . Recurrence
Introduction
Due to earlier diagnosis and improvement in cancer
treatments, cancer survivors are living longer after an initial
diagnosis of cancer [1]. Cancer is now often considered a
chronic illness rather than a life-threatening disease [2].
However with longer survival after initial diagnosis, the
number of cancer survivors experiencing disease progres-
sion (DP) such as a recurrence, a metastasis or a new tumor
could also increase [3–5]. Survivors of a first primary
cancer have an increased risk of up to 50% of developing
subsequent primary cancers [6, 7], while recurrence rates
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range from 5% to >30% for endometrial cancer, prostate
cancer, and non-Hodgkin lymphoma [8–10].
Previous studies suggest that DP can cause greater distress
than the initial cancer diagnosis [11], and is associated with
reduced psychological well-being [12–16], poorer physical
functioning [12, 17], high symptom burden [15, 18], and
poorer health-related quality of life (HRQL) [19, 20].
However, most of these studies focused on breast cancer,
had small sample sizes, had no comparison with a disease-
free control group or had short follow-up since DP. To our
knowledge, no study has explored the association between
DP, survival time since progression, and HRQL of long-term
cancer survivors (i.e. patients who are alive >5 years since
initial diagnosis).
In this secondary analysis of a cancer survivorship study
whose details are reported elsewhere [21], we aim to
investigate the effects of DP on health status (HS) and
HRQL of long-term survivors of cancer of the endometrium
or prostate, or Hodgkin’s or non-Hodgkin’s lymphoma. In
specific, we hypothesized that DP survivors will have poorer
HS and HRQL compared with patients who remain disease-
free (DF) after initial diagnosis.
Methods
Setting and participants
From the Eindhoven Cancer Registry (ECR), all patients
diagnosed with either Hodgkin’s lymphoma or non-
Hodgkin’s lymphoma between 1989 and 1998, or endo-
metrial or prostate cancer between 1994 and 1998 were
eligible for participation in a population-based cross-
sectional survey. Hodgkin’s and non-Hodgkin’s lympho-
ma have a longer inclusion period to increase the sample
size. The ECR records data on all patients newly
diagnosed with cancer in the southern part of the Nether-
lands, an area with 2.3 million inhabitants, 10 hospitals
with 18 locations and two large radiotherapy institutes
[22]. After excluding all persons who had died prior to 1
November 2004 (as according to the Central Bureau for
Genealogy which collects information on all deceased
Dutch citizens via the civil municipal registries), data
collection started in November 2004. A local certified
Medical Ethics Committee approved of this study.
Additional details of the study methodology have been
described elsewhere [21].
Clinical characteristics
Patients’ sociodemographic and clinical information were
available from the ECR. The ECR routinely collects data on
tumor characteristics, including date of diagnosis, tumor grade
according to the Tumor-Node-Metastasis clinical classifica-
tion [23], clinical stage [23], treatment, and patient back-
ground characteristics including date of birth and
comorbidity at the time of diagnosis. Comorbidity was
categorized according to an adapted Charlson comorbidity
index [24]. In this study, cancer was not included as a
comorbid condition. Socioeconomic status was determined
by an indicator developed by Statistics Netherlands based on
individual fiscal data from the year 2000 on the economic
value of the home and household income, and provided as
aggregate level for each postal code (average 17 households)
[25], which were then categorized into tertiles.
DP was defined as at least the first recurrence, metastasis
or new primary tumor experienced since initial diagnosis.
DP was indicated by patients in the self-report question-
naire. Patients were asked to report on any DP and the
month/year that this was diagnosed. Affirmative answers
were then confirmed by registry staff against ECR records,
together with information on the date of this new diagnosis
and subsequent treatment received. For DP patients,
survival time was calculated from the date of last DP
diagnosis to time of survey. If the date of last diagnosis was
not available from ECR records, we used the date as
reported by the patient. The survival time for DF patients
was calculated from date of initial diagnosis to time of
survey. We used the term ‘survival time’ rather than ‘DF
time’ to indicate time since last diagnosis to time of study
although mortality is not an outcome in this study as we
cannot ascertain that patients are DF following DP. Patients
with DP were matched with patients who remained DF
since initial diagnosis till time of survey on: a) type of
cancer, b) cancer stage at initial diagnosis, c) tumor grade at
initial diagnosis, d) age at initial diagnosis (±2 years), e)
age at time of survey (±5 years) and f) number of years
since initial diagnosis (±3 years).
Data collection
Cancer survivors were informed of the study via a letter
from their (ex)-attending physician. The letter explained
that the completion and return of the enclosed questionnaire
indicate patient’s consent to participation in the study and to
agree to the linkage of the questionnaire data with their
disease history in the ECR. Patients were reassured that
non-participation had no consequences on their follow-up
care or treatment. Non-respondents were sent a reminder
letter within 2 months.
Measures
Generic health status was assessed with the Dutch version
of the SF-36 questionnaire [26]. The SF-36 has 36 items
measuring eight dimensions of health status: physical
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functioning, role limitations due to physical problems, role
limitations due to emotional problems, social functioning,
mental health, vitality, bodily pain, and general health
perceptions. Items in each dimension are added together to
form subscale scores, which are transformed to a 0–100
scale, with higher scores indicating better perceived health.
The eight subscale scores can be further combined into the
physical (PCS) and mental (MCS) component summary
score. For the SF-36, differences of ≥5 points in the general
health domain [27], 6.5 points in the physical domain and
7.9 points in the mental health domain were considered
clinically meaningful [28]. We determined clinically mean-
ingful differences for other subscales with Norman’s ‘rule
of thumb’, whereby an ≈0.5 SD difference indicates a
threshold of discriminant change in HRQL scores of a
chronic illness [29]. The internal consistency and reliability
of all scales had Cronbach alpha values above 0.70 as
recommended for group comparisons.
The validated Dutch version of the Quality of Life–
Cancer Survivors (QOL-CS) questionnaire assessed HRQL
issues specific to cancer survivors [30]. The QOL-CS
includes 45 visual analogue scales, with each ranging from
0 (worst outcome) to 10 (best outcome). These 45 visual
analogue scales are grouped into four multi-item subscales
on well-being: physical, psychological, social, and spiritual.
Similarly, Norman’s rule was used to indicate clinically
significant differences [29].
Statistical analyses
All statistical analyses were performed using SAS (version
9.1 for Windows, SAS institute Inc., Cary NC). Differences
between demographic and clinical characteristics, and HS
and HRQL scores between the two groups were compared
with chi-square test or t-test where appropriate. Non-
parametric equivalents were applied when normality and
homogeneity assumptions were violated. The association
between disease progression and long-term HRQL was
investigated with linear regression analyses, with adjust-
ments for DF survival time, marital status, SES, and
comorbidity. Statistical differences were indicated if p<
0.05 and reported p-values were two-sided.
Results
Of the eligible survivors, 1511 (80%) returned a completed
questionnaire (Fig. 1). Details of the data collection process
for the whole sample, and the baseline characteristics of
respondents and non-respondents have been discussed
elsewhere [21]. From the respondents, 232 DP survivors
(13 Hodgkin’s lymphoma, 53 non-Hodgkin’s lymphoma,
19 endometrial cancer, and 147 prostate cancer) were
matched with 232 DF survivors of similar clinical and
demographic characteristics (Table 1). No differences on
the relevant clinical and demographic characteristics indi-
cated a successful match of the two groups. Comparison on
other demographic and clinical variables suggested that DP
survivors had more comorbid conditions and were less
likely to be working than DF survivors. Among the DP
survivors, 30 had a second DP. The time since last
progression to the date of completion of questionnaire
was, on average, 3.4±3.3 years.
Table 2 outlines the HS and HRQL scores of DP and DF
survivors. Although statistical significant differences in all
dimensions of generic HS between both groups were noted,
clinically significant differences were observed in the
dimensions of general health, physical function, role
function physical, role function emotional, and the physical
component score. On the cancer-specific QOL-CS, DP
survivors had statistically poorer scores on physical,
psychological, social, and total well-being, but not spiritual
well-being. However, only the differences in physical,
social, and total well-being scores showed clinical signif-
icance. Similar HS and HRQL results were found between
both the DP and DF groups when analysis was limited to
either prostate cancer survivors or survivors of endometrial
cancer and the lymphomas (excluding prostate cancer) (data
not shown).
The generic HS of DF and DP survivors was compared
with that of a normative population, standardized for age.
DF survivors had better HS than the normative population
on all dimensions of the SF-36, with physical functioning,
bodily pain, social functioning, role functioning emotional,
and physical component summary score statistically signif-
icantly better than that of the normative population (Fig. 2).
Among the DP group with known time of progression,
survival time was dichotomized into short (<5 years) and
long (≥5 years) survival since progression. Compared with
the normative population, the short DP group had statisti-
cally significantly poorer HS scores on all dimensions
except on bodily pain. Clinically significant differences
between the two groups were noted in general health and
mental component summary scores. Similarly, the long DP
group had poorer HS than the normative population,
although only general health and the mental component
summary scores showed statistically but not clinically
significant differences. However long DP survivors report
having better HS than short DP survivors (Table 3). Long
DP survivors exhibited significantly better mental compo-
nent summary score and the difference in general health
scores approached significance. For those DP patients (n=
29) whose date of DP were not known, their HS scores
were generally compatible with those of the long DP
survivors (data not shown).
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In univariate analyses, DP independently predicted
HS and HRQL except for spiritual well-being (data not
shown). Similarly, DF time was associated with most
dimensions of the SF-36 and QOL-CS except for bodily
pain and spiritual well-being (data not shown). In
multivariate analyses, DP remained a significant predic-
tor on most dimensions of the SF-36 and QOL-CS
(Table 4). However, the association of DF time with HS
and HRQL was reduced in the multivariate model,
remaining significant only in the dimensions of role
functioning emotional, mental health, mental component
summary score, and total well-being. Poorer scores on all
domains of the SF-36 and QOL-CS (except for spiritual
well-being) were independently predicted by comorbidity
in both univariate and multivariate analyses.
Discussion
As hypothesized, our study showed that DP cancer
survivors had poorer HS and HRQL than DF cancer
survivors of similar clinical manifestation and age. Patients
with DP within 5 years of our study reported the lowest HS
and HRQL. Cancer survivors who remain DF up to 10 years
since initial diagnosis have HS and HRQL better or
comparable to an age-matched normative population.
Moreover, DP and comorbid conditions predicted that
aspects of long-term HS and HRQL would be lower.
Compared with DF survivors, DP survivors had clini-
cally significant poorer scores on several aspects of HS and
HRQL, namely that of physical, social, and psychological
functioning. Similarly in a matched study, Oh, et al
reported that survivors with recurrent breast cancer had
poorer HRQL on multiple domains compared with DF
survivors [19]. Survivors of multiple cancers had also
poorer global HRQL, lower vitality, more cancer-specific
stress and lower existential well-being compared with
survivors of single primary cancer [31]. In another study,
breast cancer survivors with and without recurrence had
similar HRQL scores at baseline. At 8-years follow-up,
although the HRQL of disease-free survivors had improved
significantly, the HRQL scores of those with a recurrence
remained similar to their baseline assessment [13].
Higher prevalence of comorbid conditions among DP
survivors could partly explain their perceived poorer
physical and social aspects of HS and HRQL. Moreover,
comorbidity was a significant predictor of HS and HRQL in
our multivariate analysis. Similarly in a study using
CaPSURE data, prostate cancer survivors with moderate to
severe cardiovascular comorbidity had significantly poorer
physical component scale scores over 24 months follow-up
compared with patients with no comorbidity [32]. A study
of cervical cancer survivors also reported significant
association between comorbidity and HRQL [33].
Although we performed a cross-sectional study, our
results suggest that long-term DP survivors do report better
FIGURE 1 Flow-chart of the
data collection process.
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Table 1 Demographic and clinical characteristics of patients by disease status
No progression (n=232) Disease progression (n=232) p-value
Types of cancer (%)
Hodgkin’s lymphoma 13 (6) 13 (6)
Non-Hodgkin’s lymphoma 53 (23) 53 (23)
Endometrial cancer 19 (8) 19 (8)
Prostate cancer 147 (63) 147 (63)
Mean age at time of survey 69.0±10.4 68.8±10.3 0.40
Age at time of survey (%)
<55 23 (10) 21 (9)
55–64 39 (17) 41 (18)
65–74 94 (40) 97 (42) 0.87
75–84 73 (31) 72 (31)
>85 3 (1) 1 (0.4)
Mean years since diagnosis of initial cancer 8.2±1.7 8.2±1.8 0.72
Marital status (%)
Married 169 (76) 178 (77)
Single/Divorced 26 (12) 26 (11) 0.97
Widowed 26 (12) 26 (11)
Educational levela (%)
Low 108 (49) 98 (44)
Medium 66 (30) 87 (39) 0.14
High 46 (21) 36 (17)
Employment status (%)
Not working/ retired 185 (84) 201 (88) 0.03
Working 35 (16) 28 (12)
Socioeconomic status (%)
Low 49 (21) 51 (22)
Medium 97 (42) 92 (40) 0.97
High 77 (33) 79 (34)
Stage (%)
1 74 (32) 75 (32)
2 107 (46) 106 (46) 0.99
3 16 (7) 15 (6)
4 35 (15) 36 (16)
Tumor Gradeb (%)
Good 55 (24) 53 (22)
Moderate 76 (33) 76 (33)
Poor 35 (15) 36 (16) 0.97
Undifferentiated 0 1 (0.4)
T-cell (lymphoma) 2 (1) 3 (1)
B-cell (lymphoma) 51 (22) 50 (21)
Comorbidity (%)
None 91 (39) 75 (32)
1 90 (39) 82 (35) 0.04
>1 51 (22) 75 (32)
Most common comorbid conditions (%)
Hypertension 60 (26) 62 (27) 0.83
Arthritis 51 (22) 61 (26) 0.28
Diabetes mellitus 23 (10) 32 (14) 0.19
Asthma 27 (12) 29 (13) 0.77
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HS and HRQL scores over time. DP patients with shorter
survival time since last diagnosis had significantly poorer
HS and HRQL compared with an age-standardized norma-
tive population. However, we noted that DP survivors with
a progression ≥5 years ago had higher HS and HRQL
scores than those with shorter survival time since last
diagnosis. That we only found a significant difference in
the mental component summary score between these two
groups could be due to lack of power from the small sample
of long DP survivors. A longitudinal study showed that
patients with recurrent cancer had poorer HRQL compared
with single diagnosis patients at 12 months follow-up,
although the HRQL among the group with recurrence
showed improvement over time [17]. Moreover, in that
study while patients in both groups reported improved
psychological well-being over time, patients with a recur-
rence had better psychological well-being at baseline and
follow-up than patients with a single diagnosis. Similarly, a
Swedish longitudinal study with recurrent breast cancer
survivors reported a significant decrease in distress at
6 months follow-up [34]. This suggests that cancer
survivors might initially be distressed with the diagnosis
of DP [11, 13] but do have the resilience to adapt and cope
with the new diagnosis and subsequent treatment over time.
Gotay, et al found that survivors of multiple primary
cancers coped better with the second diagnosis than the
first [31]. Together with our current results, these studies
suggest that previous experiences with cancer and its
treatment could buffer a patient from the psychological
distress of coping with DP and subsequent treatment. This
reconceptualization of HRQL over the course of the disease
trajectory has been termed ‘response shift’, and refers to the
changes in self-evaluation of HRQL as cancer survivors
adapt to their disease and treatment [35]. We further
Table 1 (continued)
No progression (n=232) Disease progression (n=232) p-value
Mean years since disease progression 3.4±3.3
Years since disease progressionc (%)
< 2 years 94 (40)
2–5 years 58 (24)
>5 years 51 (21)
a Education: Low (no or primary school); Medium (lower general secondary education or vocational training); High (pre-university education,
high vocational training, university)
b 13 patients with Hodgkin’s lymphoma were matched excluding the criterion tumor grade as these were not available
c 29 patients have unknown date of progression
Disease progression (n=232 ) No progression (n=232 ) p-value
SF-36
General health 48.9±23.5 62.9±22.1 <0.0001a
Physical function 60.5±29.7 73.2±25.0 <0.0001a
Role function–physical 48.0±45.7 70.1±40.1 <0.0001a
Bodily pain 69.8±27.0 78.2±22.9 <0.001
Vitality 57.0±24.3 67.5±20.8 <0.0001
Social functioning 72.6±26.9 83.5±21.4 <0.0001
Role function–emotional 64.6±44.1 86.5±28.7 <0.0001a
Mental health 70.8±20.7 77.5±16.8 <0.001
PCS 40.0±11.7 46.0±9.8 <0.0001a
MCS 49.0±11.2 51.0±8.7 <0.0001
QOL-CS
Physical well-being 7.2±1.9 8.0±1.8 <0.0001a
Psychological well-being 5.9±1.8 6.9±1.6 <0.0001
Social well-being 6.6±1.7 7.2±1.7 <0.0001a
Spiritual well-being 4.6±1.7 4.8±1.4 n.s.
Total well-being 6.1±1.4 6.8±1.3 <0.0001a
Table 2 Mean scores (± SD) of
SF-36 and QOL-CS by disease
status
PCS Physical Component
Summary score, MCS Mental
Component Summary score,
QOL-CS Quality of Life–Cancer
Survivors
a indicates that the difference
in the HRQL score is also
clinically significant
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postulate that DP survivors with ≥5 years since progression
could potentially believe that they are DF similar to the
commonly held assumption cancer survivors in general
have that they are ‘cured’ if they remain DF >5 years since
initial diagnosis.
Response shift could also explain the significantly better
physical health reported by DF survivors when compared to
a normative population. Having survived cancer and
remaining DF for up to 15 years since initial diagnosis
could improve survivors’ self-evaluation of HRQL. DF
survivors finding benefit following their cancer diagnosis
and its subsequent cure could also impact on their HRQL.
In a study of 96 breast cancer survivors of whom the
majority remained DF, baseline benefit finding predicted
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FIGURE 2 Comparison of SF-36 scores according to disease status
to the normative population standardized for age. An asterisk above a
subgroup indicates a difference in the mean score between that
subgroup and the normative population. PCS=Physical Component
Summary score. MCS=Mental Component Summary score. **p<
0.001; *p<0.05. ξ Indicates clinically significant difference in mean
score between the subgroup and the norm population.
<5years (n=143) ≥5years (n=50) p-value
SF-36
General health 47.1±23.8 54.2±23.8 0.05
Physical function 59.2±30.6 63.2±28.9 0.51
Role function–physical 45.1±45.7 53.8±45.3 0.27
Bodily pain 69.9±26.2 70.7±29.5 0.66
Vitality 56.2±23.5 60.8±26.6 0.20
Social functioning 72.0±26.2 74.3±32.1 0.20
Role function–emotional 61.1±44.9 72.6±40.4 0.16
Mental health 69.4±21.3 74.5±20.0 0.10
PCS 39.6±11.5 41.1±12.7 0.48
MCS 47.7±11.2 51.5±11.1 0.03
QOL-CS
Physical well-being 7.1±2.0 7.5±1.8 0.17
Psychological well-being 5.8±1.9 6.1±1.6 0.45
Social well-being 6.5±1.7 6.8±1.5 0.35
Spiritual well-being 4.5±1.5 4.9±1.7 0.13
Total well-being 6.0±1.4 6.3±1.3 0.19
Table 3 Mean scores (± SD) of
SF-36 and QOL-CS of patients
with disease progression by sur-
vival time since progressiona
PCS Physical Component
Summary Score, MCS Mental
Component Summary Score,
QOL-CS Quality of Life–Cancer
Survivors
a time since progression is
missing for 29 patients
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better self-reported HRQL and positive emotion at follow-
up 4 to 7 years after initial assessment [36].
Although studies suggest that patients with DP do adapt
well to the new diagnosis over time, one study found that
patients’ beliefs could impact on the adaptation process. In
that study, breast cancer survivors with high baseline beliefs
of personal control over their disease symptoms and who
subsequently experienced a recurrence had poorer physical
and mental functioning at 5-year follow-up compared with
survivors with similar baseline beliefs who remained
disease-free [37]. Higher symptom burden was associated
with higher level of distress and decreased HRQL of
women with recurrent breast cancer at 6 months follow-up
[34].
These results have implications for clinical practice. As
the numbers of cancer survivors is increasing, the number
of cancer survivors experiencing DP will also increase.
Although current results support our hypothesis that
patients with DP have poorer HS and HRQL compared
with DF survivors, our results also suggest that time can
attenuate the distress of experiencing progression of their
disease. Therefore, besides interventions to prevent DP,
psycho-educational programs designed with an understand-
ing of cancer survivors’ attributions of recurrence could
help to increase empowerment and personal control in
patients’ self-management of illness- and treatment-related
symptoms should DP occur.
We acknowledge several limitations in our study. The
inclusion of long-term survivors raises the possibility of
survival bias in our sample selection. Moreover, the cross-
sectional design of our study limits the determination of
causal association between DP and HRQL as baseline
HRQL of patients at diagnosis is not known. Therefore,
future studies of incident cancer patients with baseline data
before DP occur and followed longitudinally would be
useful in exploring this association between DP and long-
term HRQL, and the subsequent adaptation process to DP.
Third, DP was established by patients’ self-report and
thereafter confirmed via the ECR. Therefore, it is possible
that there is an under-reporting of DP from patients who
had progression but did not report on the questionnaire.
Although our results suggest that DP survivors with longer
survival time since last diagnosis had better HS and HRQL
than those with shorter survival time, these results should
be interpreted with caution due to the relatively small
number of DP survivors with ≥5 years survival time (n=
50). Nevertheless, this result is intriguing and warrants
further research. Future prospective studies with a larger
group of DP survivors followed over a longer period could
investigate if our current results are reflective of “survival
of the fittest” or that HRQL does improve with time
following DP. Also of interest will be the identification of
predictors of better HRQL among DP survivors.Ta
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Strong points of our study include the HS and HRQL
assessments of patients with DP up to 15 years since initial
cancer diagnosis. Moreover, inclusion of the length of time
since DP for consideration when assessing long-term HS
and HRQL in cancer survivors has, to our knowledge, not
been reported previously.
Conclusions
Cancer survivors who experience DP report poorer long-
term HS and HRQL compared with disease-free survivors.
However, results suggest that DP survivors do report
better HS and HRQL over time.
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